Literature DB >> 12068066

PKC and Raf-1 inhibition-related apoptotic signalling in N2a cells.

Agnieszka Bronisz1, Barbara Gajkowska, Krystyna Domańska-Janik.   

Abstract

In this study, a neuroblastoma N2a cell line was applied to investigate mechanisms of apoptosis induced either by selective inhibition of protein kinase C (PKC) by low amounts of staurosporine (STS(10) ) or by inhibition PI3-K after wortmannin (WM) treatment. We present evidence that, in the absence of serum in the medium, decreased phosphorylation of Raf-1 and BAD112, as well as Akt and BAD136, proteins and their translocation to mitochondria coincided with STS10 - or WM-induced apoptosis, respectively. Concomitantly, release of cytochrome c into the cytosol indicated a BCL-2-dependent mode of cell death after both treatments. Furthermore, in typical 'gain of function' experiments, cells with overexpression of permanently active Raf-1 or Akt transgenes displayed a significantly higher and independent resistance to either STS10 or WM. Thus, our results indicate that PKC/Raf-1/BAD112, as well as PI3-K/Akt/BAD136 signalling pathways, are both necessary for N2a cell survival and thus are unable to functionally substitute for each other as long as the cells do not receive additional signal(s) derived from serum. However, in the presence of serum, undefined trophic signal(s) can stimulate cross-talk between these two pathways at a level upstream from Raf-1 and Akt phosphorylation. In this case, only simultaneous inhibition of PKC and PI3-K is able to induce apoptosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12068066     DOI: 10.1046/j.1471-4159.2002.00896.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  2 in total

1.  Alterations in protein kinase C activity and processing during zinc-deficiency-induced cell death.

Authors:  Susan S Chou; Michael S Clegg; Tony Y Momma; Brad J Niles; Jodie Y Duffy; George P Daston; Carl L Keen
Journal:  Biochem J       Date:  2004-10-01       Impact factor: 3.857

2.  Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine.

Authors:  Weili Sun; Shakeel Modak
Journal:  Onco Targets Ther       Date:  2012-03-02       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.